Results 151 to 160 of about 1,245,074 (217)

CD8+ Regulatory T Cells. [PDF]

Annu Rev Immunol
Vuttaradhi VK, Vermelle CM, Choi JY, Niu L, Tang X, Azzi JR, Cantor H.   +6 more
europepmc   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Regulatory T cells in cardiac allograft vasculopathy: from mechanistic insights to clinical tolerance. [PDF]

Front Immunol
Li B, Su Y, Hao Y, Ye W, Wang S, Li X, Li R, Zheng K, Zou Z, Li Y, Tao Z, Wu J, Zhang X, Xia J.   +13 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Proteomic Insights Into Human Induced Regulatory T Cells: The Role of LPXN and CD160 in Immune Suppression. [PDF]

Mol Cell Proteomics
Batkulwar K, Andrabi SBA, Kattelus R, Buchacher T, Arnkil I, Starskaia I, Rasool O, Moulder R, Lahesmaa R.   +8 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Response to Comments on Raineri et al. Memory Regulatory T Cells as a Biomarker of Early Type 1 Diabetes. [PDF]

Diabetes
Raineri D, Chiocchetti A.
europepmc   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Molecular heterogeneity and clonal origin of CCR8⁺ effector regulatory T cells in human cancer. [PDF]

Nat Commun
Swatler J, Puccio S, Voulaz E, Marulli G, Wheeler M, Sambanthamoorthy S, Scamardella E, Feno S, Testa S, Camisaschi C, Errico V, Simonelli M, Losurdo A, Mazza EMC, Lugli E.   +14 more
europepmc   +1 more source